ID P5F1B_HUMAN Reviewed; 359 AA.
AC Q06416; D5K9S4; D5K9S9; D5K9T0; D5K9T1; D5K9T3; D5K9U3; D5K9U6; D5K9V4;
AC D5K9V6; D5K9W0; D5K9W2; D5K9W7; D5K9X2; D5K9X3; D5K9X5; D5K9X8; D5K9X9;
AC E9LRB1; E9LRB2; E9LRH5; E9LRH6; E9LRH7; E9LRK4; E9LRK5; E9LRK7; E9LRK8;
AC E9LRM7; E9LRM9; E9LRN2; E9LRN4; E9LRN5; E9LRP8; E9LRQ0; E9LRQ2; E9LRQ3;
AC E9LRQ4; E9LRQ5; E9LRS3; Q2VIK6; Q9BZV7; Q9BZV9;
DT 01-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT 16-NOV-2011, sequence version 2.
DT 24-JAN-2024, entry version 180.
DE RecName: Full=Putative POU domain, class 5, transcription factor 1B;
DE AltName: Full=Oct4-pg1;
DE AltName: Full=Octamer-binding protein 3-like;
DE AltName: Full=Octamer-binding transcription factor 3-like;
GN Name=POU5F1B;
GN Synonyms=OCT4PG1, OTF3C, OTF3P1, POU5F1P1, POU5FLC20, POU5FLC8;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC TISSUE=Liver;
RX PubMed=1408763; DOI=10.1093/nar/20.17.4613;
RA Takeda J., Seino S., Bell G.I.;
RT "Human Oct3 gene family: cDNA sequences, alternative splicing, gene
RT organization, chromosomal location, and expression at low levels in adult
RT tissues.";
RL Nucleic Acids Res. 20:4613-4620(1992).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=16201836; DOI=10.1371/journal.pbio.0030357;
RA Marques A.C., Dupanloup I., Vinckenbosch N., Reymond A., Kaessmann H.;
RT "Emergence of young human genes after a burst of retroposition in
RT primates.";
RL PLoS Biol. 3:E357-E357(2005).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS THR-182 AND ASP-214.
RC TISSUE=Kidney;
RA van Roozendaal K.E.P., Gillis A.J.M., van Asseldonk M., Oosterhuis J.W.,
RA Looijenga L.H.J., van Zoelen E.J.J.;
RT "Identification and expression analysis of novel intron-less human
RT POU5F1/OCT3 related POU domain genes.";
RL Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC TISSUE=Mammary cancer;
RA Zhao F.-Q., Buss K.;
RT "Differential expression of Oct-4 gene and pseudogene in normal and breast
RT cancer cells.";
RL Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS ARG-33; GLU-176; THR-182; ASP-214 AND
RP GLN-238, AND TISSUE SPECIFICITY.
RC TISSUE=Glial tumor, and Mammary cancer;
RX PubMed=21341266; DOI=10.1002/path.2827;
RA Zhao S., Yuan Q., Hao H., Guo Y., Liu S., Zhang Y., Wang J., Liu H.,
RA Wang F., Liu K., Ling E.A., Hao A.;
RT "Expression of OCT4 pseudogenes in human tumours: lessons from glioma and
RT breast carcinoma.";
RL J. Pathol. 223:672-682(2011).
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=16421571; DOI=10.1038/nature04406;
RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA Platzer M., Shimizu N., Lander E.S.;
RT "DNA sequence and analysis of human chromosome 8.";
RL Nature 439:331-335(2006).
RN [7]
RP TISSUE SPECIFICITY.
RX PubMed=16229821; DOI=10.1016/j.bbrc.2005.09.157;
RA Suo G., Han J., Wang X., Zhang J., Zhao Y., Zhao Y., Dai J.;
RT "Oct4 pseudogenes are transcribed in cancers.";
RL Biochem. Biophys. Res. Commun. 337:1047-1051(2005).
RN [8]
RP FUNCTION, AND SUBCELLULAR LOCATION.
RX PubMed=18949397;
RA Panagopoulos I., Moeller E., Collin A., Mertens F.;
RT "The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1
RT isoform 1.";
RL Oncol. Rep. 20:1029-1033(2008).
CC -!- FUNCTION: Shows weak transcriptional activator activity.
CC {ECO:0000269|PubMed:18949397}.
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00108,
CC ECO:0000255|PROSITE-ProRule:PRU00530, ECO:0000269|PubMed:18949397}.
CC -!- TISSUE SPECIFICITY: Detected at the mRNA level in several cancer
CC tissues (breast, uterine cervix, lung, thyroid gland, esophagus, colon,
CC urinary bladder, and glioma), but absent in normal tissues.
CC {ECO:0000269|PubMed:16229821, ECO:0000269|PubMed:21341266}.
CC -!- SIMILARITY: Belongs to the POU transcription factor family. Class-5
CC subfamily. {ECO:0000305}.
CC -!- CAUTION: Could be the product of a pseudogene. Several pseudogenes of
CC POU5F1 have been described on chromosomes 1, 3, 8, 10 and 12. Two of
CC them, localized on chromosomes 8 and 10 have been shown to be
CC preferentially transcribed in cancer tissues and may be involved in the
CC regulation of POU5F1 gene activity in carcinogenesis. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; Z11901; CAA77953.1; -; Genomic_DNA.
DR EMBL; DQ120688; ABB92462.1; -; Genomic_DNA.
DR EMBL; AF268615; AAG53083.1; -; mRNA.
DR EMBL; AF268618; AAG53085.1; -; mRNA.
DR EMBL; DQ486513; ABF29403.1; -; mRNA.
DR EMBL; GU480835; ADE48561.1; -; mRNA.
DR EMBL; GU480840; ADE48566.1; -; mRNA.
DR EMBL; GU480841; ADE48567.1; -; mRNA.
DR EMBL; GU480842; ADE48568.1; -; mRNA.
DR EMBL; GU480845; ADE48570.1; -; mRNA.
DR EMBL; GU480864; ADE48580.1; -; mRNA.
DR EMBL; GU480868; ADE48583.1; -; mRNA.
DR EMBL; GU480878; ADE48591.1; -; mRNA.
DR EMBL; GU480880; ADE48593.1; -; mRNA.
DR EMBL; GU480883; ADE48596.1; -; mRNA.
DR EMBL; GU480886; ADE48597.1; -; mRNA.
DR EMBL; GU480889; ADE48599.1; -; mRNA.
DR EMBL; GU480896; ADE48604.1; -; mRNA.
DR EMBL; GU480902; ADE48606.1; -; mRNA.
DR EMBL; GU480905; ADE48609.1; -; mRNA.
DR EMBL; GU480906; ADE48610.1; -; mRNA.
DR EMBL; GU480908; ADE48612.1; -; mRNA.
DR EMBL; GU480911; ADE48614.1; -; mRNA.
DR EMBL; GU480912; ADE48615.1; -; mRNA.
DR EMBL; GU480913; ADE48616.1; -; mRNA.
DR EMBL; HQ122710; ADW77351.1; -; mRNA.
DR EMBL; HQ122711; ADW77352.1; -; mRNA.
DR EMBL; HQ122712; ADW77353.1; -; mRNA.
DR EMBL; HQ122713; ADW77354.1; -; mRNA.
DR EMBL; HQ122714; ADW77355.1; -; mRNA.
DR EMBL; HQ122716; ADW77356.1; -; mRNA.
DR EMBL; HQ122717; ADW77357.1; -; mRNA.
DR EMBL; HQ122718; ADW77358.1; -; mRNA.
DR EMBL; HQ122719; ADW77359.1; -; mRNA.
DR EMBL; HQ122721; ADW77360.1; -; mRNA.
DR EMBL; HQ122749; ADW77385.1; -; mRNA.
DR EMBL; HQ122750; ADW77386.1; -; mRNA.
DR EMBL; HQ122751; ADW77387.1; -; mRNA.
DR EMBL; HQ122752; ADW77388.1; -; mRNA.
DR EMBL; HQ122781; ADW77415.1; -; mRNA.
DR EMBL; HQ122782; ADW77416.1; -; mRNA.
DR EMBL; HQ122783; ADW77417.1; -; mRNA.
DR EMBL; HQ122784; ADW77418.1; -; mRNA.
DR EMBL; HQ122785; ADW77419.1; -; mRNA.
DR EMBL; HQ122786; ADW77420.1; -; mRNA.
DR EMBL; HQ122787; ADW77421.1; -; mRNA.
DR EMBL; HQ122788; ADW77422.1; -; mRNA.
DR EMBL; HQ122789; ADW77423.1; -; mRNA.
DR EMBL; HQ122790; ADW77424.1; -; mRNA.
DR EMBL; HQ122816; ADW77444.1; -; mRNA.
DR EMBL; HQ122817; ADW77445.1; -; mRNA.
DR EMBL; HQ122818; ADW77446.1; -; mRNA.
DR EMBL; HQ122819; ADW77447.1; -; mRNA.
DR EMBL; HQ122820; ADW77448.1; -; mRNA.
DR EMBL; HQ122821; ADW77449.1; -; mRNA.
DR EMBL; HQ122822; ADW77450.1; -; mRNA.
DR EMBL; HQ122823; ADW77451.1; -; mRNA.
DR EMBL; HQ122824; ADW77452.1; -; mRNA.
DR EMBL; HQ122825; ADW77453.1; -; mRNA.
DR EMBL; HQ122826; ADW77454.1; -; mRNA.
DR EMBL; HQ122827; ADW77455.1; -; mRNA.
DR EMBL; HQ122841; ADW77467.1; -; mRNA.
DR EMBL; HQ122842; ADW77468.1; -; mRNA.
DR EMBL; HQ122843; ADW77469.1; -; mRNA.
DR EMBL; HQ122844; ADW77470.1; -; mRNA.
DR EMBL; HQ122845; ADW77471.1; -; mRNA.
DR EMBL; HQ122846; ADW77472.1; -; mRNA.
DR EMBL; HQ122848; ADW77473.1; -; mRNA.
DR EMBL; HQ122849; ADW77474.1; -; mRNA.
DR EMBL; HQ122851; ADW77475.1; -; mRNA.
DR EMBL; HQ122852; ADW77476.1; -; mRNA.
DR EMBL; HQ122853; ADW77477.1; -; mRNA.
DR EMBL; HQ122854; ADW77478.1; -; mRNA.
DR EMBL; HQ122855; ADW77479.1; -; mRNA.
DR EMBL; HQ122856; ADW77480.1; -; mRNA.
DR EMBL; HQ122857; ADW77481.1; -; mRNA.
DR EMBL; HQ122864; ADW77487.1; -; mRNA.
DR EMBL; HQ122865; ADW77488.1; -; mRNA.
DR EMBL; HQ122866; ADW77489.1; -; mRNA.
DR EMBL; HQ122867; ADW77490.1; -; mRNA.
DR EMBL; HQ122868; ADW77491.1; -; mRNA.
DR EMBL; HQ122869; ADW77492.1; -; mRNA.
DR EMBL; HQ122870; ADW77493.1; -; mRNA.
DR EMBL; HQ122871; ADW77494.1; -; mRNA.
DR EMBL; HQ122874; ADW77495.1; -; mRNA.
DR EMBL; HQ122876; ADW77496.1; -; mRNA.
DR EMBL; HQ122877; ADW77497.1; -; mRNA.
DR EMBL; HQ122878; ADW77498.1; -; mRNA.
DR EMBL; HQ122879; ADW77499.1; -; mRNA.
DR EMBL; HQ122880; ADW77500.1; -; mRNA.
DR EMBL; HQ122881; ADW77501.1; -; mRNA.
DR EMBL; HQ122882; ADW77502.1; -; mRNA.
DR EMBL; HQ122883; ADW77503.1; -; mRNA.
DR EMBL; HQ122884; ADW77504.1; -; mRNA.
DR EMBL; HQ122885; ADW77505.1; -; mRNA.
DR EMBL; HQ122886; ADW77506.1; -; mRNA.
DR EMBL; HQ122887; ADW77507.1; -; mRNA.
DR EMBL; HQ122891; ADW77511.1; -; mRNA.
DR EMBL; HQ122892; ADW77512.1; -; mRNA.
DR EMBL; HQ122893; ADW77513.1; -; mRNA.
DR EMBL; HQ122895; ADW77514.1; -; mRNA.
DR EMBL; HQ122898; ADW77515.1; -; mRNA.
DR EMBL; HQ122900; ADW77516.1; -; mRNA.
DR EMBL; HQ122902; ADW77517.1; -; mRNA.
DR EMBL; HQ122903; ADW77518.1; -; mRNA.
DR EMBL; AC016883; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR CCDS; CCDS55274.1; -.
DR RefSeq; NP_001153014.1; NM_001159542.1.
DR AlphaFoldDB; Q06416; -.
DR SMR; Q06416; -.
DR STRING; 9606.ENSP00000419298; -.
DR GlyGen; Q06416; 1 site, 1 O-linked glycan (1 site).
DR iPTMnet; Q06416; -.
DR PhosphoSitePlus; Q06416; -.
DR BioMuta; POU5F1B; -.
DR DMDM; 357528826; -.
DR jPOST; Q06416; -.
DR MassIVE; Q06416; -.
DR MaxQB; Q06416; -.
DR PaxDb; 9606-ENSP00000419298; -.
DR PeptideAtlas; Q06416; -.
DR Antibodypedia; 54266; 117 antibodies from 21 providers.
DR DNASU; 5462; -.
DR Ensembl; ENST00000465342.4; ENSP00000419298.2; ENSG00000212993.6.
DR Ensembl; ENST00000645438.1; ENSP00000495779.1; ENSG00000212993.6.
DR Ensembl; ENST00000696633.1; ENSP00000512769.1; ENSG00000212993.6.
DR GeneID; 5462; -.
DR KEGG; hsa:5462; -.
DR MANE-Select; ENST00000696633.1; ENSP00000512769.1; NM_001159542.3; NP_001153014.1.
DR UCSC; uc003ysf.4; human.
DR AGR; HGNC:9223; -.
DR CTD; 5462; -.
DR DisGeNET; 5462; -.
DR GeneCards; POU5F1B; -.
DR HGNC; HGNC:9223; POU5F1B.
DR HPA; ENSG00000212993; Tissue enhanced (choroid).
DR MIM; 615739; gene.
DR neXtProt; NX_Q06416; -.
DR OpenTargets; ENSG00000212993; -.
DR PharmGKB; PA33547; -.
DR VEuPathDB; HostDB:ENSG00000212993; -.
DR eggNOG; KOG3802; Eukaryota.
DR GeneTree; ENSGT00940000155046; -.
DR HOGENOM; CLU_066243_0_0_1; -.
DR InParanoid; Q06416; -.
DR OMA; YTQADMG; -.
DR OrthoDB; 4250502at2759; -.
DR PhylomeDB; Q06416; -.
DR TreeFam; TF316413; -.
DR PathwayCommons; Q06416; -.
DR BioGRID-ORCS; 5462; 315 hits in 1072 CRISPR screens.
DR GenomeRNAi; 5462; -.
DR Pharos; Q06416; Tbio.
DR Proteomes; UP000005640; Chromosome 8.
DR RNAct; Q06416; Protein.
DR Bgee; ENSG00000212993; Expressed in primordial germ cell in gonad and 77 other cell types or tissues.
DR Genevisible; Q06416; HS.
DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR GO; GO:0005829; C:cytosol; IDA:HPA.
DR GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:UniProtKB.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:UniProtKB.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR CDD; cd00086; homeodomain; 1.
DR Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR Gene3D; 1.10.260.40; lambda repressor-like DNA-binding domains; 1.
DR InterPro; IPR009057; Homeobox-like_sf.
DR InterPro; IPR017970; Homeobox_CS.
DR InterPro; IPR001356; Homeobox_dom.
DR InterPro; IPR010982; Lambda_DNA-bd_dom_sf.
DR InterPro; IPR013847; POU.
DR InterPro; IPR000327; POU_dom.
DR PANTHER; PTHR11636; POU DOMAIN; 1.
DR PANTHER; PTHR11636:SF86; POU DOMAIN, CLASS 5, TRANSCRIPTION FACTOR 1-RELATED; 1.
DR Pfam; PF00046; Homeodomain; 1.
DR Pfam; PF00157; Pou; 1.
DR PRINTS; PR00028; POUDOMAIN.
DR SMART; SM00389; HOX; 1.
DR SMART; SM00352; POU; 1.
DR SUPFAM; SSF46689; Homeodomain-like; 1.
DR SUPFAM; SSF47413; lambda repressor-like DNA-binding domains; 1.
DR PROSITE; PS00027; HOMEOBOX_1; 1.
DR PROSITE; PS50071; HOMEOBOX_2; 1.
DR PROSITE; PS00035; POU_1; 1.
DR PROSITE; PS00465; POU_2; 1.
DR PROSITE; PS51179; POU_3; 1.
PE 5: Uncertain;
KW Activator; DNA-binding; Homeobox; Nucleus; Phosphoprotein;
KW Reference proteome; Transcription; Transcription regulation.
FT CHAIN 1..359
FT /note="Putative POU domain, class 5, transcription factor
FT 1B"
FT /id="PRO_0000100753"
FT DOMAIN 138..212
FT /note="POU-specific"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00530"
FT DNA_BIND 229..288
FT /note="Homeobox"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT REGION 1..53
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 87..116
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 287..322
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 90..113
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 111
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q01860"
FT MOD_RES 235
FT /note="Phosphothreonine"
FT /evidence="ECO:0000250|UniProtKB:Q01860"
FT MOD_RES 236
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q01860"
FT MOD_RES 288
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q01860"
FT MOD_RES 289
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q01860"
FT MOD_RES 354
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:Q01860"
FT VARIANT 33
FT /note="L -> R (in dbSNP:rs1061394)"
FT /evidence="ECO:0000269|PubMed:21341266"
FT /id="VAR_067432"
FT VARIANT 69
FT /note="L -> F (in dbSNP:rs1061395)"
FT /id="VAR_067433"
FT VARIANT 176
FT /note="G -> E (in dbSNP:rs6998061)"
FT /evidence="ECO:0000269|PubMed:21341266"
FT /id="VAR_067434"
FT VARIANT 182
FT /note="K -> T (in dbSNP:rs13273814)"
FT /evidence="ECO:0000269|PubMed:21341266, ECO:0000269|Ref.3"
FT /id="VAR_067435"
FT VARIANT 214
FT /note="N -> D (in dbSNP:rs13274084)"
FT /evidence="ECO:0000269|PubMed:21341266, ECO:0000269|Ref.3"
FT /id="VAR_067436"
FT VARIANT 238
FT /note="E -> Q (in dbSNP:rs7002225)"
FT /evidence="ECO:0000269|PubMed:21341266"
FT /id="VAR_067437"
FT VARIANT 313
FT /note="P -> L (in dbSNP:rs556361752)"
FT /id="VAR_067438"
FT CONFLICT 10
FT /note="A -> T (in Ref. 5; ADE48599)"
FT /evidence="ECO:0000305"
FT CONFLICT 13
FT /note="P -> L (in Ref. 5; ADE48609/ADW77452)"
FT /evidence="ECO:0000305"
FT CONFLICT 14
FT /note="P -> T (in Ref. 5; ADW77351)"
FT /evidence="ECO:0000305"
FT CONFLICT 23..25
FT /note="WGA -> GGP (in Ref. 5; ADE48566/ADE48597)"
FT /evidence="ECO:0000305"
FT CONFLICT 31
FT /note="D -> G (in Ref. 5; ADE48567)"
FT /evidence="ECO:0000305"
FT CONFLICT 31
FT /note="D -> V (in Ref. 5; ADE48570)"
FT /evidence="ECO:0000305"
FT CONFLICT 35
FT /note="W -> R (in Ref. 5; ADW77415/ADW77416/ADW77417/
FT ADW77420/ADW77421)"
FT /evidence="ECO:0000305"
FT CONFLICT 39
FT /note="Q -> R (in Ref. 5; ADE48583)"
FT /evidence="ECO:0000305"
FT CONFLICT 76
FT /note="C -> R (in Ref. 5; ADW77445)"
FT /evidence="ECO:0000305"
FT CONFLICT 79
FT /note="Q -> H (in Ref. 5; ADW77469)"
FT /evidence="ECO:0000305"
FT CONFLICT 91
FT /note="E -> V (in Ref. 5; ADE48610/ADW77455)"
FT /evidence="ECO:0000305"
FT CONFLICT 106
FT /note="N -> S (in Ref. 5; ADE48612)"
FT /evidence="ECO:0000305"
FT CONFLICT 107
FT /note="S -> Y (in Ref. 5; ADW77513/ADW77518)"
FT /evidence="ECO:0000305"
FT CONFLICT 129
FT /note="L -> Q (in Ref. 5; ADE48580)"
FT /evidence="ECO:0000305"
FT CONFLICT 130
FT /note="E -> G (in Ref. 5; ADW77492)"
FT /evidence="ECO:0000305"
FT CONFLICT 132
FT /note="N -> D (in Ref. 5; ADW77447)"
FT /evidence="ECO:0000305"
FT CONFLICT 138
FT /note="D -> G (in Ref. 5; ADE48599)"
FT /evidence="ECO:0000305"
FT CONFLICT 150
FT /note="A -> T (in Ref. 5; ADE48616)"
FT /evidence="ECO:0000305"
FT CONFLICT 152
FT /note="L -> F (in Ref. 5; ADW77351)"
FT /evidence="ECO:0000305"
FT CONFLICT 155
FT /note="Q -> R (in Ref. 5; ADW77490/ADW77499/ADW77502/
FT ADW77503)"
FT /evidence="ECO:0000305"
FT CONFLICT 160
FT /note="L -> P (in Ref. 5; ADW77417)"
FT /evidence="ECO:0000305"
FT CONFLICT 163
FT /note="T -> A (in Ref. 5; ADE48580)"
FT /evidence="ECO:0000305"
FT CONFLICT 169
FT /note="L -> F (in Ref. 5; ADW77415/ADW77420/ADW77421)"
FT /evidence="ECO:0000305"
FT CONFLICT 169
FT /note="L -> P (in Ref. 5; ADE48561)"
FT /evidence="ECO:0000305"
FT CONFLICT 169
FT /note="L -> R (in Ref. 5; ADE48583)"
FT /evidence="ECO:0000305"
FT CONFLICT 196
FT /note="N -> D (in Ref. 5; ADW77492)"
FT /evidence="ECO:0000305"
FT CONFLICT 197
FT /note="M -> I (in Ref. 1; CAA77953)"
FT /evidence="ECO:0000305"
FT CONFLICT 201
FT /note="R -> W (in Ref. 5; ADE48615)"
FT /evidence="ECO:0000305"
FT CONFLICT 208
FT /note="V -> E (in Ref. 5; ADW77493/ADW77501/ADW77506)"
FT /evidence="ECO:0000305"
FT CONFLICT 211
FT /note="A -> T (in Ref. 5; ADE48593/ADW77355/ADW77358/
FT ADW77387/ADW77418/ADW77423)"
FT /evidence="ECO:0000305"
FT CONFLICT 235
FT /note="T -> A (in Ref. 5; ADW77518/ADW77513)"
FT /evidence="ECO:0000305"
FT CONFLICT 241
FT /note="V -> M (in Ref. 5; ADW77488/ADW77496/ADW77504/
FT ADW77507)"
FT /evidence="ECO:0000305"
FT CONFLICT 246
FT /note="E -> G (in Ref. 5; ADW77492)"
FT /evidence="ECO:0000305"
FT CONFLICT 249
FT /note="F -> L (in Ref. 5; ADW77474/ADW77481)"
FT /evidence="ECO:0000305"
FT CONFLICT 250
FT /note="L -> P (in Ref. 5; ADE48580)"
FT /evidence="ECO:0000305"
FT CONFLICT 250
FT /note="L -> Q (in Ref. 5; ADW77475)"
FT /evidence="ECO:0000305"
FT CONFLICT 259
FT /note="I -> T (in Ref. 5; ADW77488/ADW77496/ADW77504/
FT ADW77507)"
FT /evidence="ECO:0000305"
FT CONFLICT 264
FT /note="Q -> H (in Ref. 5; ADE48609/ADW77452)"
FT /evidence="ECO:0000305"
FT CONFLICT 264
FT /note="Q -> L (in Ref. 5; ADW77477/ADW77476/ADW77467)"
FT /evidence="ECO:0000305"
FT CONFLICT 272
FT /note="V -> M (in Ref. 5; ADW77472/ADW77479)"
FT /evidence="ECO:0000305"
FT CONFLICT 276..278
FT /note="WFC -> CFG (in Ref. 5; ADW77495)"
FT /evidence="ECO:0000305"
FT CONFLICT 282
FT /note="Q -> R (in Ref. 5; ADW77494)"
FT /evidence="ECO:0000305"
FT CONFLICT 284
FT /note="G -> S (in Ref. 5; ADW77469)"
FT /evidence="ECO:0000305"
FT CONFLICT 295
FT /note="E -> V (in Ref. 5; ADE48583)"
FT /evidence="ECO:0000305"
FT CONFLICT 318
FT /note="H -> Q (in Ref. 5; ADW77444/ADW77445)"
FT /evidence="ECO:0000305"
FT CONFLICT 321
FT /note="T -> I (in Ref. 5; ADW77476/ADW77467/ADW77477)"
FT /evidence="ECO:0000305"
FT CONFLICT 326
FT /note="S -> G (in Ref. 5; ADW77444/ADW77445)"
FT /evidence="ECO:0000305"
FT CONFLICT 331
FT /note="A -> T (in Ref. 5; ADW77447/ADW77448/ADW77451)"
FT /evidence="ECO:0000305"
FT CONFLICT 340
FT /note="E -> V (in Ref. 5; ADE48570)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 359 AA; 38588 MW; 9AF853B116FCB75A CRC64;
MAGHLASDFA FSPPPGGGGD GPWGAEPGWV DPLTWLSFQG PPGGPGIGPG VGPGSEVWGI
PPCPPPYELC GGMAYCGPQV GVGLVPQGGL ETSQPESEAG VGVESNSNGA SPEPCTVPPG
AVKLEKEKLE QNPEKSQDIK ALQKELEQFA KLLKQKRITL GYTQADVGLI LGVLFGKVFS
QKTICRFEAL QLSFKNMCKL RPLLQKWVEE ADNNENLQEI CKAETLMQAR KRKRTSIENR
VRGNLENLFL QCPKPTLQIS HIAQQLGLEK DVVRVWFCNR RQKGKRSSSD YAQREDFEAA
GSPFSGGPVS FPPAPGPHFG TPGYGSPHFT ALYSSVPFPE GEVFPPVSVI TLGSPMHSN
//
